LIGAND PHARMACEUTICALS INC
No enriched coverage for $LGND in the last 7 days.
Reardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $304.07 ($302.51–$307.74, $1.52M total) across 6 trades on 2026-10-02 under a Rule 10b5-1 trading plan.
Ligand Pharmaceuticals (LGND) agreed to provide up to $47M in funding to AvenCell Therapeutics, tied to clinical milestones and future royalties. This deal expands Ligand's royalty-focused model without increasing internal R&D. Analysts project $481.1M revenue and $273.9M earnings by 2029, with a 10% potential upside.
Ligand Pharmaceuticals (LGND) announced a $47M financing deal with AvenCell Therapeutics, including $6M for Series C funding and $41M for drug development, tied to milestones. Ligand aims for mid-single-digit to low-double-digit royalties on AvenCell's sales. The company's royalty revenue grew 32% YoY to $48M in Q2, with a target of $225M-$250M for 2026. Ligand has $1.36B in cash and $700M for further investments.
Recent LGND coverage spans insider activity, financial news and corporate actions.
In the last 30 days, LGND insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($1.5M). The most active reporter was Reardon Andrew, CLO & Secretary, with 6 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may signal confidence concerns, likely creating short-term selling pressure.
The funding expands Ligand's royalty pipeline without increasing R&D spend, which may be viewed positively by investors.
The deal expands Ligand's royalty pipeline and could boost future royalty revenue, but carries execution risk.
Potential upside of ~15% may attract buying interest.
Overweight initiation suggests upside.
AlphAI scores every news story that mentions LGND with an AI model for sentiment and relevance, and aggregates insider trades from LIGAND PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Reardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $304.07 ($302.51–$307.74, $1.52M total) across 6 trades on 2026-10-02 under a Rule 10b5-1 trading plan.
1 min readLigand Pharmaceuticals (LGND) agreed to provide up to $47M in funding to AvenCell Therapeutics, tied to clinical milestones and future royalties. This deal expands Ligand's royalty-focused model without increasing internal R&D. Analysts project $481.1M revenue and $273.9M earnings by 2029, with a 10% potential upside.
2 min readLigand Pharmaceuticals (LGND) announced a $47M financing deal with AvenCell Therapeutics, including $6M for Series C funding and $41M for drug development, tied to milestones. Ligand aims for mid-single-digit to low-double-digit royalties on AvenCell's sales. The company's royalty revenue grew 32% YoY to $48M in Q2, with a target of $225M-$250M for 2026. Ligand has $1.36B in cash and $700M for further investments.
2 min readBarclays initiated coverage of Ligand Pharmaceuticals (LGND) with an Outperform rating, citing potential for over 20% long-term revenue growth. The bank set a $345 price target, implying ~15% upside from Sept. 24 levels.
1 min readAnalysts made multiple rating changes: Wells Fargo initiated Johnson Controls (JCI) as overweight, UBS initiated Chemed (CHE) as buy, Mizuho reiterated SpaceX as outperform, Barclays initiated Ligand Pharmaceuticals (LGND) as overweight, Seaport reiterated Nvidia (NVDA) as sell, UBS upgraded Stem (STEM) to buy, HSBC upgraded BP (BP) to buy, Bernstein initiated CF Industries (CF) as outperform, Bank of America reiterated AMD (AMD) as buy, Bernstein reiterated Apple (AAPL) as outperform, JPMorgan…
3 min readLigand Pharmaceuticals (LGND) invested up to $47M in AvenCell for a royalty on sales of its pipeline, including AVC-201 for AML and AVC-203 for B-cell malignancies. Funding is in four tranches tied to milestones. CEO Todd Davis highlighted AvenCell's technology and data.
2 min readLIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., September 24, 2026 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a f
1 min readLIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receiv
2 min readZimmermann Martine sold 1,200 shares of LIGAND PHARMACEUTICALS INC (LGND) at $285.00 ($0.34M total) on 2026-09-10.
1 min readReardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $286.09 ($283.99–$288.98, $1.43M total) across 5 trades on 2026-09-03 under a Rule 10b5-1 trading plan.
1 min read
